Skip to content
Tiagabine
Gabitril (tiagabine) is a small molecule pharmaceutical. Tiagabine was first approved as Gabitril on 1997-09-30. It is used to treat bipolar disorder, epilepsy, and partial epilepsies in the USA. The pharmaceutical is active against sodium- and chloride-dependent GABA transporter 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Gabitril (generic drugs available since 2011-11-04)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tiagabine hydrochloride
Tradename
Company
Number
Date
Products
GABITRILCephalonN-020646 RX1997-09-30
4 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
gabitrilNew Drug Application2020-12-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bipolar disorderEFO_0000289D001714F30.9
epilepsyEFO_0000474D004827G40.9
partial epilepsiesEFO_0004263D004828—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AG: Fatty acid derivatives, antiepileptics
— N03AG06: Tiagabine
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTIAGABINE
INNtiagabine
Description
Tiagabine is a piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy. It has a role as a GABA reuptake inhibitor and an anticonvulsant. It is a piperidinemonocarboxylic acid, a beta-amino acid, a member of thiophenes and a tertiary amino compound. It is functionally related to a (R)-nipecotic acid. It is a conjugate base of a tiagabine(1+).
Classification
Small molecule
Drug classgabamimetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C
Identifiers
PDB—
CAS-ID115103-54-3
RxCUI31914
ChEMBL IDCHEMBL1027
ChEBI ID9586
PubChem CID60648
DrugBankDB00906
UNII IDZ80I64HMNP (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A1
SLC6A1
Organism
Homo sapiens
Gene name
SLC6A1
Gene synonyms
GABATR, GABT1, GAT1
NCBI Gene ID
6529
Protein name
sodium- and chloride-dependent GABA transporter 1
Protein synonyms
GABA transporter 1, solute carrier family 6 (neurotransmitter transporter), member 1, solute carrier family 6 (neurotransmitter transporter, GABA), member 1, Solute carrier family 6 member 1
Uniprot ID
Q8N4K8
Mouse ortholog
Slc6a1 (232333)
sodium- and chloride-dependent GABA transporter 1 (P31648)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Gabitril - Cephalon
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,136 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
357 adverse events reported
View more details